Key result
Short steric-blocking antisense oligonucleotides inhibit HCV IRES-mediated translation and preinitiation complex formation in vitro.
Why the study?
Current antiviral regimens for hepatitis C virus infection are not satisfactory, necessitating the development of novel, specific anti-HCV antiviral drugs.
Answers are grounded in this paper and cite their sources.
Hepatitis C virus (HCV) infection represents a worldwide problem, and current antiviral regimens are not satisfactory. The need to develop novel, specific, anti-HCV antiviral drugs is clear. Antisense oligonucleotides (AS-ON), ribozymes, and more recently, small interfering RNAs (siRNAs) have been widely used to control gene expression, and several clinical trials are in progress. The potential to use AS-ON as tools to control HCV infection, either by promoting an RNase H mediated cleavage of viral genomic RNA or by interfering with the assembly of a translation initiation complex on the internal ribosome entry site (IRES) is reviewed. Extensive knowledge of IRES structure and conservation among HCV genotypes have rendered the HCV IRES (and, in particular, its IIId loop) particularly attractive for antisense approaches. Encouraging data have been obtained with IRES-targeted RNase H-competent and incompetent ON analogs. We demonstrate here that very short steric blocking ONs can inhibit the formation of translation preinitiation complexes on the IRES and block IRES-mediated translation in a cell-free translation assay and in a transfected hepatoma cell line.
No takes yet. Share an insight, caveat, or question.
Martinand‐Mari et al. (2003) conducted a review in Hepatitis C Virus (HCV) infection. Antisense oligonucleotides targeting IRES was evaluated. Very short steric blocking antisense oligonucleotides can inhibit the formation of translation preinitiation complexes on the HCV IRES and block IRES-mediated translation in vitro.
Synapse has enriched 10 related papers. Consider them for comparative context: